Börse:
13,112€
-3,36%
Echtzeit-Aktienkurs MacroGenics
Bid:
12,968€
Ask:
13,256€
| Allgemeine Informationen | ||
|---|---|---|
| Börsenwert: | 555,33 Mio. EUR (42,35 Mio. x 13,112€) | |
| Website: | - | |
| Sektor: | Medizin / Biotechnologie | |
| News-Radar | |
|---|---|
| dpa-AFX Pro - | Newsbot - |
| dpa-AFX - | Reuters - |
| 2016 | 2017 | 2018 | |
|---|---|---|---|
| KUV | 4,98 | 3,06 | 9,24 |
| KGV | - | - | - |
| Div. Rend. | - | - | - |
Echtzeit-Chart der MacroGenics Aktie
Börsenkurse MacroGenics
| Euro Indikation | 12,968€ | 0 | 13,256€ | 0 | 13,112€ | -3,36% |
| Börse Stuttgart | 12,968€ | 0 | 13,256€ | 0 | 13,112€ | 0,21% |
| Tradegate | 12,972€ | 462 | 13,242€ | 453 | 13,107€ | -3,40% |
| Lang & Schwarz | 13,066€ | 915 | 13,170€ | 915 | 13,118€ | -2,10% |
| Dollar Indikation | 14,574$ | 0 | 14,864$ | 0 | 14,719$ | -2,78% |
Fundamentaldaten der MacroGenics Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2018 | 60,12 Mio. | -171,45 Mio. | -171,45 Mio. | -4,19 | 0,00% | - | 9,24 |
| 2017 | 157,74 Mio. | -19,63 Mio. | -19,63 Mio. | -0,54 | 0,00% | - | 3,06 |
| 2016 | 91,88 Mio. | -58,53 Mio. | -58,53 Mio. | -1,69 | 0,00% | - | 4,98 |
Profil der MacroGenics Aktie
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. It is focused on three therapeutic areas: Oncology, Autoimmune Disorders and Infectious Diseases. The company's proprietary technology platforms include Dual-Affinity Re-Targeting (DART) Therapeutics, which allow to incorporate multiple specificities within a single molecule; FC Optimization, enhances antibody-dependent functions; and Cancer Stem Cell, which provides a unique discovery tool to identify cancer targets shared by both tumor-initiating cells and differentiated cancer cells. Its infectious disease portfolio includes antibody-based therapeutics for the treatment of infectious diseases from pathogens, such as dengue, smallpox and H5N1. The company's autoimmune program, teplizumab, is an anti-CD3 antibody developed for the prevention and treatment of early onset diabetes. MacroGenics was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
TraderFox GmbH:
Impressum & Datenschutz -
Allgemeine Geschäftsbedingungen